Skip to content
OpenCapital
Get started

Oric Pharmaceuticals, Inc. ORIC Cash ratio

Cash ratio at other companies

Pfizer logo
PfizerPFE
0.1×0.0×
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
2.5×-1.4×
CG Oncology logo
CG OncologyCGON
1×-0.9×
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
1.1×-0.8×
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
6.1×+1.1×
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
3.8×-2.3×

Other financials

Income statement

See full
Operating income-$39.6M-21.1%
Net income-$35.8M-19.1%
EPS (diluted)-$0.34+19.0%

Balance sheet

See full
Cash & equivalents$56.4M+14.3%
Total debt$3.3M+2.6%
Total equity$415.6M+89.1%
Total assets$436.8M+79.8%

Cash flow

See full
Operating cash flow-$32.4M+0.3%
CapEx$2.0K-99.5%
Free cash flow-$32.4M+1.5%

Valuation

See full
Market cap$976.17M+23.4%
Enterprise value$923.07M+23.9%

Returns & leverage

See full
Return on equity-42.6%-4.6pp
Debt / equity0×0.0×
Current ratio16.3×+4.3×

Where this comes from

Calculated from Oric Pharmaceuticals, Inc.’s reported figures.

cash and equivalents/total current liabilities=3.2×

Based on the most recent quarter.

The official record: Oric Pharmaceuticals, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oric Pharmaceuticals, Inc.'s cash ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Oric Pharmaceuticals, Inc.'s cash ratio?
Oric Pharmaceuticals, Inc. (ORIC) reported cash ratio of 3.2× in Q1 2026.
How has Oric Pharmaceuticals, Inc.'s cash ratio changed year-over-year?
Oric Pharmaceuticals, Inc.'s cash ratio increased by 13.3% year-over-year, from 2.8× to 3.2×.
What is the long-term trend for Oric Pharmaceuticals, Inc.'s cash ratio?
Over 5 years (2020 to 2025), Oric Pharmaceuticals, Inc.'s cash ratio has grown at a -23.8% compound annual growth rate (CAGR), from 8.7× to 2.2×.
What does cash ratio mean?
Cash and equivalents divided by current liabilities at the quarter end. The most conservative liquidity measure — what the company could pay immediately with cash on hand.